Alchemab Therapeutics, a next-generation biopharmaceutical company, has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready program for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. The transaction is worth up to a total of $415 million, including an undisclosed upfront payment, potential discovery, development, and commercialization payments and royalties. Under the terms of the agreement...